JP2018515552A - 避妊用組成物ならびに有効性改善および副作用調節方法 - Google Patents

避妊用組成物ならびに有効性改善および副作用調節方法 Download PDF

Info

Publication number
JP2018515552A
JP2018515552A JP2017560243A JP2017560243A JP2018515552A JP 2018515552 A JP2018515552 A JP 2018515552A JP 2017560243 A JP2017560243 A JP 2017560243A JP 2017560243 A JP2017560243 A JP 2017560243A JP 2018515552 A JP2018515552 A JP 2018515552A
Authority
JP
Japan
Prior art keywords
shbg
progestin
amount
ligand
estrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017560243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515552A5 (https=
Inventor
エイジス・キドニエウス
マイケル・イー・カフリッセン
ケイティ・マクファーレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agile Therapeutics Inc
Original Assignee
Agile Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agile Therapeutics Inc filed Critical Agile Therapeutics Inc
Publication of JP2018515552A publication Critical patent/JP2018515552A/ja
Publication of JP2018515552A5 publication Critical patent/JP2018515552A5/ja
Priority to JP2021117119A priority Critical patent/JP2021169503A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017560243A 2015-05-18 2016-05-18 避妊用組成物ならびに有効性改善および副作用調節方法 Pending JP2018515552A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021117119A JP2021169503A (ja) 2015-05-18 2021-07-15 避妊用組成物ならびに有効性改善および副作用調節方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562163113P 2015-05-18 2015-05-18
US62/163,113 2015-05-18
US201562254999P 2015-11-13 2015-11-13
US62/254,999 2015-11-13
PCT/US2016/033024 WO2016187269A1 (en) 2015-05-18 2016-05-18 Contraceptive compositions and methods for improved efficacy and modulation of side effects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021117119A Division JP2021169503A (ja) 2015-05-18 2021-07-15 避妊用組成物ならびに有効性改善および副作用調節方法

Publications (2)

Publication Number Publication Date
JP2018515552A true JP2018515552A (ja) 2018-06-14
JP2018515552A5 JP2018515552A5 (https=) 2019-06-20

Family

ID=56116539

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017560243A Pending JP2018515552A (ja) 2015-05-18 2016-05-18 避妊用組成物ならびに有効性改善および副作用調節方法
JP2021117119A Pending JP2021169503A (ja) 2015-05-18 2021-07-15 避妊用組成物ならびに有効性改善および副作用調節方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021117119A Pending JP2021169503A (ja) 2015-05-18 2021-07-15 避妊用組成物ならびに有効性改善および副作用調節方法

Country Status (10)

Country Link
US (3) US20180125860A1 (https=)
EP (1) EP3297634A1 (https=)
JP (2) JP2018515552A (https=)
CN (1) CN107995864A (https=)
AU (2) AU2016264137B2 (https=)
BR (1) BR112017024783A2 (https=)
CA (1) CA2986039A1 (https=)
HK (1) HK1251938A1 (https=)
MX (1) MX2017014768A (https=)
WO (1) WO2016187269A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
US20200129524A1 (en) * 2017-03-15 2020-04-30 Agile Therapeutics, Inc. Personalized contraceptive formulations
CN111989105B (zh) 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509218A (ja) * 1992-03-02 1995-10-12 シエーリング　アクチエンゲゼルシヤフト エストロゲン／プロゲスチン／アンチプロゲスチン方法並びに経口避妊及び月経調整のためのキット
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
JPH1129481A (ja) * 1997-06-23 1999-02-02 Medical College Of Hampton Roads 月経の出血を少なくし維持された効力を持つ超低投与量避妊薬
US20030073673A1 (en) * 1997-09-11 2003-04-17 Rolf-Dieter Hesch Hormonal contraceptive product
JP2007513938A (ja) * 2003-12-12 2007-05-31 シエーリング アクチエンゲゼルシャフト 浸透増強剤を必要としないホルモンの経皮送達
JP2007524648A (ja) * 2003-07-17 2007-08-30 アジル・セラピューティクス・インコーポレイテッド 経皮ホルモン送達システム：組成物および方法
WO2014100599A1 (en) * 2012-12-21 2014-06-26 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents
JP2015508750A (ja) * 2012-01-27 2015-03-23 アジル・セラピューティクス・インコーポレイテッドＡｇｉｌｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 経皮ホルモン送達

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
US4863738A (en) 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US7704983B1 (en) * 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
CN1188189C (zh) 1995-06-07 2005-02-09 奥瑟－麦内尔制药公司 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US6251956B1 (en) * 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
BR0015802B1 (pt) * 1999-11-24 2014-04-29 Agile Therapeutics Inc Sistema de administração de contraceptivo transdérmico, e, método para produzir um sistema de administração de contraceptivo transdérmico
ATE485837T1 (de) 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
CN1672685A (zh) * 2004-03-26 2005-09-28 董可娟 一种新的避孕药物
US20100178323A1 (en) * 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
CA2704117C (en) 2007-11-02 2015-11-17 Acrux Dds Pty Ltd Transdermal delivery system
ES2734510T3 (es) * 2008-10-08 2019-12-10 Agile Therapeutics Inc Administración transdérmica
CA2740004A1 (en) * 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
US9198919B2 (en) * 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
EP2410859A4 (en) * 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509218A (ja) * 1992-03-02 1995-10-12 シエーリング　アクチエンゲゼルシヤフト エストロゲン／プロゲスチン／アンチプロゲスチン方法並びに経口避妊及び月経調整のためのキット
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
JPH1129481A (ja) * 1997-06-23 1999-02-02 Medical College Of Hampton Roads 月経の出血を少なくし維持された効力を持つ超低投与量避妊薬
US20030073673A1 (en) * 1997-09-11 2003-04-17 Rolf-Dieter Hesch Hormonal contraceptive product
JP2007524648A (ja) * 2003-07-17 2007-08-30 アジル・セラピューティクス・インコーポレイテッド 経皮ホルモン送達システム：組成物および方法
JP2007513938A (ja) * 2003-12-12 2007-05-31 シエーリング アクチエンゲゼルシャフト 浸透増強剤を必要としないホルモンの経皮送達
JP2015508750A (ja) * 2012-01-27 2015-03-23 アジル・セラピューティクス・インコーポレイテッドＡｇｉｌｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 経皮ホルモン送達
WO2014100599A1 (en) * 2012-12-21 2014-06-26 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents

Also Published As

Publication number Publication date
HK1251938A1 (zh) 2019-05-03
US20240156838A1 (en) 2024-05-16
AU2021262853B2 (en) 2024-05-09
CN107995864A (zh) 2018-05-04
CA2986039A1 (en) 2016-11-24
JP2021169503A (ja) 2021-10-28
US20250319102A1 (en) 2025-10-16
AU2021262853A1 (en) 2021-12-02
EP3297634A1 (en) 2018-03-28
BR112017024783A2 (pt) 2018-08-07
AU2016264137B2 (en) 2021-08-19
WO2016187269A1 (en) 2016-11-24
MX2017014768A (es) 2018-03-23
AU2016264137A1 (en) 2018-01-18
US20180125860A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
US20250319102A1 (en) Contraceptive compositions and methods for improved efficacy and modulation of side effects
Regidor The clinical relevance of progestogens in hormonal contraception: present status and future developments
Sitruk-Ware et al. Contraception technology: past, present and future
JP5184727B2 (ja) 女性への非経口アンドロゲンステロイドの投与
Bennink et al. Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women
EP1390041B1 (en) Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
AU667729B2 (en) Minimizing progestin associated breakthrough bleeding
MXPA01009813A (es) Terapia interrumpida de reemplazo de hormonas con dosis bajas de estrogeno.
Gerrits et al. Pharmacokinetic profile of nomegestrol acetate and 17β-estradiol after multiple and single dosing in healthy women
JP2018515552A5 (https=)
WO2002094281A1 (en) Means and method for hormonal contraception
Haiba et al. Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters
US20040198707A1 (en) Means and method for hormonal contraception
CN1771024A (zh) 延长的经皮避孕方案
JP2003511399A (ja) 女性避妊薬の成分としてのメソプロゲスチン（プロゲステロン受容体モジュレーター）
US5622943A (en) Minimizing progestin associated breakthrough bleeding
RU2796919C2 (ru) Композиции для персонализированной контрацепции
US20200129524A1 (en) Personalized contraceptive formulations
JP2003513908A (ja) ホルモン補充療法（ｈｒｔ）のための組成物の成分としてのメソプロゲスチン（プロゲステロン受容体モジュレーター）
Nelson New developments in oral contraception: clinical utility of estradiol valerate/dienogest (Natazia®) for contraception and for treatment of heavy menstrual bleeding: patient considerations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190517

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201006

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210316